The process of spatial rearrangement of cells of the inner cell mass (ICM) that are destined to become hypoblast is not well understood. The observation that the chemokine (C-C motif) ligand 24 (CCL24) and several other genes involved in chemokine signaling are expressed more in the ICM than in the trophectoderm of the bovine embryo resulted in the hypothesis that CCL24 participates in spatial organization of the ICM. Temporally, expression of CCL24 in the bovine embryo occurs coincidently with blastocyst formation: transcript abundance was low until the late morula stage, peaked in the blastocyst at Day 7 of development and declined by Day 9. Treatment of embryos with two separate antagonists of C-C motif chemokine receptor 3 (the prototypical receptor for CCL24) decreased the percent of GATA6 + cells (hypoblast precursors) that were located in the outside of the ICM. Similarly, injection of zygotes with a CCL24-specific morpholino decreased the percent of GATA6 + cells in the outside of the ICM. In conclusion, CCL24 assists in spatial arrangement of the ICM in the bovine embryo. This experiment points to new functions of chemokine signaling in the bovine embryo and is consistent with the idea that cell migration is involved in the spatial organization of hypoblast cells in the blastocyst.
Introduction
Formation of the hypoblast from cells of the inner cell mass (ICM) represents the second differentiation event in the mammalian embryo, being preceded by differentiation of cells into the ICM and trophectoderm (TE). In the mouse, hypoblast formation from cells within the ICM is regulated by the fibroblast growth factor 4 (Fgf4)/fibroblast growth factor receptor 2 (Fgfr2) pathway [1] [2] [3] [4] .
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A group of cells within the ICM secretes Fgf4 that then acts on neighboring cells through Fgfr2 to activate expression of GATA binding protein 6 (Gata6) and drive hypoblast formation. The remaining cells, which are negative for Fgfr2, express Nanog homeobox (Nanog) and become epiblast cells [1] [2] [3] [4] . Initially, Gata6 + and Nanog + cells are scattered in the ICM in a salt-and-pepper pattern but subsequently Gata6 + cells form an epithelium at the edge of the ICM lining the blastocoel [3, 4] . There is species variation in the mechanisms by which hypoblast cells are delineated. In particular, Fgf4 has little or no role in formation of hypoblast in the human and bovine embryo, although downstream effectors of Fgf4 signaling participate in promotion of hypoblast differentiation and inhibition of epiblast differentiation in cattle [5] . Three models have been described to explain the mechanism by which Gata6
+ cells in the ICM become spatially reorganized into an epithelium lining the blastocoele [6] . The first model, that the cells near the blastocoel cavity are the most sensitive to signals triggering hypoblast differentiation [7] , is not consistent with the initial localization of Gata6 + cells throughout the ICM, although it is possible that there is heterogeneity among Gata6 + cells in signal responsiveness. Another model posits that localization depends on apoptosis as well as switching of gene expression from Gata6 to Nanog or vice versa depending on cell position [8, 9] . Finally, it has been proposed that hypoblast precursors move to their corresponding location [4] . Time-lapse photography has been used to demonstrate movement of Gata6 + cells across the ICM to face the blastocoel cavity [8] .
Among the genes differentially expressed between cells of the ICM and TE in the bovine blastocyst is chemokine (C-C motif) ligand 24 (CCL24), which encodes for a chemokine also known as eotaxin-2 and which was overexpressed in the ICM of the Day 8 blastocyst when compared to the TE [10] [11] [12] [13] . Other genes involved in chemokine signaling are also upregulated in ICM compared with the TE including pro-platelet basic protein (PPBP) (previously known as CXCL7), IL2-inducible T-cell kinase, and signal transducer and activator of transcription 3 [10] [11] [12] [13] . Chemokines exhibit chemotactic activity and are involved in cellular migration, polarization, and proliferation [14] [15] [16] [17] . CCL24 signals through the G-protein coupled seven transmembrane receptor C-C motif chemokine receptor 3 (CCR3) [18] .
In the present study, we tested the hypothesis that CCL24 plays a role in the arrangement of cells of the epiblast and hypoblast of the bovine embryo. The hypothesis was analyzed through a series of experiments to evaluate gene expression, protein localization, and consequences of inhibition of CCL24 signaling.
Materials and methods

In vitro production of embryos
Embryos were produced by in vitro fertilization using procedures described elsewhere [19] . Oocytes were obtained from ovaries recovered from a local abattoir. Both oocytes and sperm were from a mixture of animals of various breeds including Bos taurus, B. indicus, and admixture of the two genetic types. The surface of the ovaries was scored with a scalpel and washed in oocyte collection medium (BoviPRO, MOFA Global, Verona, WI, USA) to collect cumulus oocyte complexes (COCs). Those COCs covered with at least three layers of cumulus cells and containing homogeneous cytoplasm were selected for maturation. The selected COCs were washed in fresh oocyte collection medium, pooled in groups of 10, and placed in 50 μl drops of oocyte maturation medium (Tissue Culture Medium-199 with Earle's salts supplemented with 2% (v/v) bovine steer serum, 100 U/ml penicillin-G, 0.1 mg/ml streptomycin, and 1 mM glutamine) that were overlaid with mineral oil (Sigma-Aldrich, St. Louis, MO, USA). The COCs were matured for 18-22 h at 38.5
• C in an atmosphere of 5% (v/v) CO 2 in humidified air. Up to 300 COCs were pooled and fertilized in plates containing 1.7 ml of In Vitro Fertilization -Tyrode's Albumin Lactate Pyruvate medium (Caisson Labs, Smithfield, UT, USA) and 80 μl penicillamine-hypotaurine-epinephrine solution (0.5 mM penicillamine, 0.25 mM hypotaurine, and 25 μM epinephrine) prepared as previously described [20] . Semen from frozen-thawed straws from three bulls were pooled, purified with Isolate [Irvine Scientific, Santa Ana, CA, USA; 50% (vol/vol and 90% (vol/vol)], and diluted to a final concentration in the fertilization dishes of 1 × 10 6 /ml. Fertilization proceeded for 8-9 h in a humidified environment at 38.5
• C and 5% (v/v) CO 2 . After fertilization, putative zygotes were removed from the fertilization dish, denuded of cumulus cells by vortexing in 100 μl hyaluronidase (1000 U/ml in approximately 0.5 ml HEPES-TALP), and cultured in groups of 25-30 in 50 μl oil-covered microdrops of a serum-free culture medium called synthetic oviduct fluid-bovine embryo 2 (SOF-BE2) [21] at 38.5
• C and a humidified environment consisting of 5% (v/v) O 2 , 5% (v/v) CO 2 , and the balance nitrogen. The proportion of putative zygotes that cleaved was determined at Day 3 after insemination and the proportion that developed to blastocyst was determined at Day 7 after insemination. A replicate was defined as a single in vitro fertilization procedure; each replicate consisted of at least 300 COCs and involved fertilization with a pool of spermatozoa from three bulls. A total of 48 bulls were used for the different replicates throughout all the experiments. Only replicates with a cleavage rate ≥65% in control embryos were used.
Developmental changes in mRNA for CCL24, CCR3, and C-C motif chemokine receptor 5 (CCR5) Matured oocytes and embryos were produced in vitro. Oocytes were harvested at 18-22 h after maturation, and cumulus cells were removed using hyaluronidase as described above. Embryos were collected from cultures at the following times: 28-32 h postinsemination (hpi) (2-cell), 44-48 hpi (3-4 cell), 50-55 hpi (5-8 cell) , 72 hpi (9-16 cell), 120 hpi (Day 5 morula), 144 hpi (Day 6 morula and Day 6 blastocysts), 168 hpi (Day 7 blastocyst), 192 hpi (Day 8 blastocyst) and 216 hpi (Day 9 blastocyst). Oocytes and embryos were collected for detection of CCL24 transcripts in two experiments. In the first, 4 pools of 10-30 oocytes or embryos of the following stages were collected: matured oocyte, 2-cell, 3-4 cell, 5-8 cell, 9-16 cell, Day 5 morula, and blastocysts at Days 7-9 (840 oocytes and embryos total). In the second experiment, 3 pools each of Day 5 morula, Day 6 morula, Day 6 blastocysts, and Day 7 blastocysts were collected (360 total embryos). For detection of CCR3 and CCR5, only one pool of Day 7 blastocysts was analyzed (30 embryos total).
Pools of oocytes and embryos were washed three times in Dulbecco phosphate-buffered saline (DPBS) containing 0.1% (w/w) polyvinylpyrrolidone (PVP; Kodak, Rochester, NY, USA), incubated in 0.1% (w/v) protease from Streptococcus griseus (Sigma-Aldrich) in DPBS until the zonae dissolved, washed another three times in fresh DPBS/PVP, and stored at -80
• C until processing for RNA extraction. RNA was extracted from each pool of embryos using the RNeasy micro kit (Qiagen, Valencia, CA, USA). A DNase treatment was included in the RNA isolation procedure. Reverse transcription was performed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Carlsbad, CA, USA) following manufacturer's instructions. For each sample, a negative control in which reverse transcriptase was omitted was performed. The cDNA was stored at -20 • C until further use.
Primers for glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta (YWHAZ) housekeeping genes were used as previously described [22] . Primers for CCL24 (Fwd: 5 -TAGAGGGCTCTTGGTCACA-3 ; Rv: 5 -GTCCTCC AGGTCCATTCATTAC-3 ), CCR3 (Fwd: 5 -AGACTTTCTGCA GTCCTCTTTAC-3 ; Rv: 5 -AGAGCGAGACCCAGGATATTT-3 ), and CCR5 (Fwd: 5 GTGTCGCAACGAGAAGAAGA-3 ; Rv: 5 -CAGGAGAAGGACGATGTTGTAG-3 ) were designed using PrimerQuest (IDT DNA, Coralville, IA, USA). Primers were validated using pools of cDNA from 40 blastocysts, lymphocytes or blood samples, and quantitative real-time PCR. Validation included generation of a standard curve of at least three points with a two-factor dilution between two subsequent points. Slopes were between -3.00 and -3.50 and primer efficiency was between 98% and 103%. Identification of amplicons was confirmed by agarose gel electrophoresis, Sanger sequencing, and alignment of the sequence using the Basic Local Alignment Search Tool feature of the National Center for Biotechnology Information (https://blast. ncbi.nlm.nih.gov/Blast.cgi).
Reverse transcription PCR (RT-PCR) was analyzed two ways, firstly by qualitative PCR, where amplicons were examined by agarose gel electrophoresis, and secondly by quantitative real-time PCR (qPCR). The reactions were performed using the CFX96 RealTime PCR Detection System and SsoFast EvaGreen Supermix with Low ROX (Bio-Rad, Hercules, CA, USA). The conditions for both qualitative and quantitative PCR were as follows: an initial denaturation at 95
• C for 30 s followed by 40 cycles at 95
• C for 5 s, 60
• C for 5 s, and 1 cycle for a melting curve analysis at 65
• C to 95
• C in increments of 0.5
• C every 2 s [22] . The amplicons examined by gel electrophoresis were separated by electrophoresis using 1% (w/v) agarose gels in Tris acetate-EDTA buffer. Bands were visualized with 0.1 μg/ml ethidium bromide (ThermoFisher). All samples were run on a single gel at 60 V for 1 h. For qPCR, the cycle threshold (Ct) for each gene of interest was normalized to the geometric mean of GAPDH and YWHAZ reference genes to generate Ct values that were used for statistical analysis.
Production of antisera to CCL24
Mouse antibovine CCL24 polyclonal antiserum was developed by immunizing three Balb/C mice with a mix of three peptides that were each conjugated to keyhole limpet hemocyanin. The peptides were H 2 N-CQKKASARARAMSTT-OH, H 2 N-AGVIFTTQKGQKFC-OH, and H 2 N-SKKIPESRVISYQLC-OH. They corresponded to regions of bovine CCL24 (NP_001040061.1) predicted to be antigenic. Each mouse was immunized with 125 μl of a solution of 1.9-2.0 mg/ml of each peptide conjugate that was mixed with 125 μl MPL + TDM Emulsion oil (2× concentration; Sigma-Aldrich) and 10 μl of 1 mg/ml CpG stock (Invivogen, San Diego, CA, USA). Each mouse was immunized, s.c., at three sites (50 μl in each ventral groin site and 160 μl on the back). Immunization was repeated three times at 21-day intervals. A final intraperitoneal injection of 125 μl without adjuvant (i.e., peptide conjugates only) was administered at 88 days after the first immunization. Blood was collected from each mouse at various intervals and tested for antibody titer by enzyme-linked immunosorbent assay (ELISA). Isotype of the antiserum was determined by using three alkaline-phosphatase-labeled secondary antibodies in the ELISA: rabbit antimouse IgG, whole molecule; goat antimouse IgG, gamma chain specific; and goat antimouse IgM, mu chain specific. The sample of serum producing the highest titer (collected on Day 92 after initial immunization) was used for experiments. This antiserum had an IgG titer that was 16-fold higher than the IgM titer. Specificity of the antiserum was confirmed by neutralization of the antiserum with the conjugated peptides mixture followed by ELISA and immunofluorescence.
Immunolocalization of CCL24 and caudal type homeobox 2 (CDX2)
Dual labeling for immunoreactive CCL24 and CDX2 was examined in Days 5 (n = 16) and 6 (n = 13) morulae and Days 7 (n = 93) and 8 (n = 96) blastocysts. All steps proceeded at room temperature. Embryos were again washed, incubated for 1 h in mouse monoclonal antibody against CDX2 (Biogenex, Fremont, CA, USA) at the 1 μg/ml working concentration provided by the manufacturer. Embryos were washed and incubated with the secondary antibody consisting of 1 μg/ml Alexa555 conjugated rabbit polyclonal antimouse IgG. Finally, embryos were washed and incubated in 1 μg/ml Hoescht 33342 in DPBS/PVP to label nuclei, washed in DPBS/PVP, placed on a glass microscope slide in 10 μl drops of SlowFade Gold antifade reagent (ThermoFisher Scientific, Waltham, MA, USA), covered with a coverslip and observed with a 40X objective using a Zeiss Axioplan 2 epifluorescence microscope (Zeiss, Göttingen, Germany) and Zeiss filter sets 02 [4 ,6-diamidino-2-phenylindole (DAPI)], 03 (FITC), and 04 (rhodamine). Digital images were acquired using AxioVision software (Zeiss) and a high-resolution black and white Zeiss AxioCam MRm digital camera. Image J V. 1.48 (National Institutes of Health, Bethesda, MD, USA) was used to visualize images and measure labeling intensity.
To determine nonspecific labeling, primary antibodies were replaced with normal mouse serum [1:100 (v/v)] and mouse IgG (1 μg/ml).
Consequences of inhibition of CCR3 for localization of Gata6
+ cells in hypoblast
Two experiments were conducted to determine effects of inhibition of CCR3 on localization of hypoblast cells. One experiment utilized (S)-methyl-2-naphthoylamino-3-(4-nitrophenyl) propionate (SB328437; Calbiochem, Billerica, MA, USA) [23, 24] and the second utilized N-benzoyl-4-nitroaniline ethyl ester (SB297006; R&D Systems, Minneapolis, MN, USA) [24] . In each experiment, embryos were cultured in 45 μl SOF-BE2. At Day 6 postinsemination, each drop of embryos received 5 μl of inhibitor [SB328437 (final . Concentrations used were shown to be effective at inhibiting eosinophil chemotaxis [23, 24] . Blastocysts were collected at Day 8 after insemination for immunolocalization of Gata6 (hypoblast) and NANOG (epiblast). The number of embryos subjected to analysis was 8-9 embryos per group for the experiment with SB328437 (from two different replicates) and 68 embryos per group for SB297006 (from six different replicates). Procedures for immunofluorescent labeling were as described above except that the primary antibodies (both used at 1 μg/ml) were mouse polyclonal antibody against human NANOG (eBioscience, San Diego, CA, USA) and rabbit polyclonal antibody against human Gata6 (Santa Cruz Biotechnology, Dallas, TX, USA). The secondary antibodies were 1 μg/ml FITC-conjugated goat polyclonal antimouse IgG (Abcam) and Alexa Fluor 555-conjugated goat polyclonal antirabbit IgG (ThermoFisher).
Embryos were examined for immunofluorescence using confocal microscopy. Embryos were placed in 10 μl drops of ProLong Gold Anti-Fade Mounting Medium (ThermoFisher Scientific) on clean chamber slides and examined on a spinning disk confocal scanner mounted on an Olympus DSU-IX81 inverted fluorescent microscope. Images were captured with a 40× objective using DAPI, FITC and red fluorescent protein filter sets. Digital images were taken every 2 μm using an attached Hamamatsu C4742-80-12AG monochrome CCD camera. SlideBook 6 Reader (Intelligent Imaging Innovations, Inc., Denver, CO, USA) was used to visualize images and count total number of cells. Images visualized and captured following confocal microscopy were counted by sections. Embryos contained a total of 23 sections on average. Eppendorf, Hauppauge, NY, USA). Presumptive zygotes were placed in a medium of DPBS containing 1 μM morpholino and injected using a holding pipette (15-20 μm internal diameter, 120 μm outer diameter, 0.65 mm tip to elbow length; Smiths Medical, Dublin, OH, USA) and an injection pipette (spiked tip, 5 μm internal diameter, 0.55 mm tip to elbow length; Smiths Medical). The injection solution was loaded into the tip of the pipette each time before microinjection until the formed meniscus reached the curve of the pipette. The pipette was advanced into the zygote and, through application of negative pressure, the plasma membrane was ruptured. Then, positive pressure was applied to return the cytoplasm into the zygote along with the injection solution. The volume was regulated by observing the meniscus reaching the tip of the pipette. It was estimated that 10-11 pl was injected based on the internal diameter and the length of the tip of the pipette. Zygotes were visualized under a digital inverted fluorescent microscope (Evos FL, Thermo Fisher Scientific). Those zygotes in which fluorescence was detected (indicating successful injection of the fluorescently tagged morpholino) were cultured in microdrops of SOF-BE2 as described earlier until Day 7 or 8 after insemination for PCR and immunohistochemical analysis, respectively. A total of 60 zygotes for each morpholino group were cultured for each replicate. An additional negative control for the microinjection procedure was a group of 60 uninjected embryos per replicate that were exposed to the same manipulation conditions as the microinjected embryos but that were placed in DPBS during micromanipulation and were not injected.
Randomly selected blastocysts at Day 7 of development were harvested to measure CCL24 mRNA. A total of three pools of 8-25 blastocysts per pool from three different replicates were processed for qPCR as described above. A total of 12-22 blastocysts per group from another five different replicates were collected at Day 8 and processed for immunolabeling for NANOG and Gata6 as described above. Number of NANOG + and Gata6 + cells and location of Gata6 + cell in the inner and outer part of the ICM were determined as described above.
Statistical analysis
The SAS v 9.4 software package (SAS Institute Inc., Cary, NC, USA) was used for statistical analysis. Treatment effects were evaluated by analysis of variance using the generalized linear models procedure (PROC GLM) of SAS; data shown are least-squares means ± standard error of the mean (SEM). For main effects in which there were more than two levels, differences between means were determined using the pdiff statement of PROC GLM or by separating variation due to treatment into individual degree-of-freedom comparisons using orthogonal contrasts. For example, differences in localization of Gata6 + cells in the morpholino experiment were determined by separating variation due to treatment into single degree-of-freedom orthogonal contrasts to determine the difference between two controls (uninjected and standard negative morpholino) to the targeting morpholino and the difference between the uninjected control versus the standard negative morpholino.
Results
Developmental changes in expression of CCL24 in the bovine embryo
Expression of CCL24 was assessed in two experiments. In the first experiment, presence of CCL24 mRNA was evaluated by electrophoresis of PCR products (Figure 2A) . Expression of CCL24 was not detectable in the matured oocyte or in embryos at any stage of development from the 2-cell stage through 16-cell stage. Transcript for CCL24 was detected in the morula at Day 6 of development and in blastocysts at Days 7-9 of development. Amounts of mRNA were greater at Day 7 than at Day 8 or 9. In the second experiment, amounts of CCL24 mRNA were quantified for embryos collected from Days 5 to 7 of development ( Figure 2B ). There was no detectable CCL24 in Day 5 morulae but CCL24 mRNA was detectable in blastocysts at Days 6 and 7. Amounts of mRNA were greater (P = 0.01) at Day 7 than for other stages.
Immunolocalization of CCL24
Immunoreactive CCL24 was not detected in morulae collected at Day 5 or 6 (results not shown). There was also a fraction of embryos at both Days 7 (18% of the 93 embryos examined) and 8 (14% of the 96 embryos examined) that did not exhibit immunoreactive CCL24. The remaining blastocysts exhibited immunoreactive CCL24 in the cytoplasm but the pattern varied between embryos ( Figure 3 ). The most common pattern, exhibited in 43% of the Day 7 blastocysts examined and 48% of the Day 8 blastocysts examined, was for labeling in the ICM (defined as cells not labeled with CDX2) to be greater than for cells in the TE (cells positive for CDX2) ( Figure 3A ). For other blastocysts (28% at Day 7 and 32% at Day 8), labeling was similar for ICM and TE ( Figure 3B ). In a minority of cases, labeling for CCL24 was greater for TE than ICM (11% of Day 7 blastocysts and 6% of Day 8 blastocysts). Overall, intensity of labeling for CCL24, scored from 0 to 4, was greater for ICM than TE at both Days 7 and 8 (P < 0.0001; Figure  4 ). In the negative control embryos, there was no specific labeling ( Figure 3C ). Figure 5A (vehicle) and B (SB297006). For the experiment with SB328437, treatment did not cause a change in number of NANOG + ( Figure 6A ), Gata6 + ( Figure 6B ), or total cells in the ICM ( Figure   6C ). However, the inhibitor did reduce (P = 0.03) the percent of Gata6 + cells located on the outside of the ICM ( Figure 6D ). Similarly, SB297006 had no effect on number of cells in the ICM (Figure 6E -G) but reduced (P = 0.03) the percent of Gata6 + cells localized on the outside of the ICM ( Figure 6H ).
Consequences of inhibition of CCR3 for localization of
Consequences of knockdown of CCL24 for localization of Gata6 + cells in hypoblast
Microinjection decreased the percent of putative zygotes that cleaved and that became blastocysts (P < 0.01) regardless of the solution injected, but there was no difference between embryos injected with Results of a separate experiment in which expression of CCL24 relative to housekeeping genes (GAPDH and YWHAZ; n = 3 biological replicates) were determined by qPCR. Transcript for CCL24 was nondetectable for morulae at Day 5 or 6 but was detected for blastocysts at Days 6 and 7. Using statistical analysis, expression was higher for Day 7 blastocysts (P = 0.01) than for embryos at other stages. Data are least-squares means ± SEM.
the standard negative or CCL24 morpholino in cleavage rate or blastocyst development. Values for cleavage were 76.3% for uninjected, 67.6% for the standard negative control, and 64.1% for the CCL24 morpholino. Values for percent of putative zygotes developing to the blastocyst stage at Day 7 were 18.7% for uninjected (from 529 zygotes), 11.1% for standard negative control (from 477 zygotes), and 10.2% for CCL24 morpholino (from 495 zygotes). For development of blastocysts at Day 8, values were 27.0% for uninjected, 16.5% for standard negative control, and 13.3% for CCL24 morpholino. Amounts of mRNA for CCL24 in blastocysts at Day 7 were reduced for targeting morpholino as compared to the two control groups (P = 0.08) ( Figure 8A ). Labeling with anti-NANOG (epiblast) and Gata6 (hypoblast) was used to define position of hypoblast cells within the ICM.
Representative examples of labeling are shown in Figure 7A -C. Treatment did not cause a change in number of NANOG + (Figure 8B ) or Gata6 + ( Figure 8C ) in the ICM or total cells (Figure 8D) . However, the targeting morpholino reduced (P = 0.02) the percent of Gata6 + cells located on the outside of the ICM ( Figure 8E ).
Expression of CCR3 and CCR5
There was no detectable expression of CCR3 or CCR5 in the blastocyst at Day 7 or 8 of development even though primers were successful in amplifying both receptor genes from lymphocyte cDNA (results not shown). Representative examples of patterns of immunoreactive CCL24 in Days 7 and 8 blastocyst as determined by epiflourescent microscopy. Shown are two representative embryos. Note that immunoreactivity was greater for ICM than TE for one embryo (A), whereas immunoreactive CCL24 (green) was present in both ICM and TE for another embryo (B). The ICM, which was identified by lack of immunolabeling of CDX2 (red), is outlined in white. Panel (C) shows an example of a negative control embryo labeled with normal mouse serum (NMS) and mouse IgG (mIgG) instead of CCL24 and CDX2. All nuclei were labeled with Hoescht (blue). Scale bar = 10 μM.
Discussion
One of the poorly understood phenomena involved in hypoblast formation is the reorganization of the ICM by which Gata6 + cells change from being distributed throughout the ICM to being limited to an epithelial layer lining the blastocoele [6] . Cell movement has been proposed to be involved in this process [4] , and Gata6 + cells have been shown to move across the ICM [8] . The observation that 10 genes involved in the chemokine signaling pathway are overexpressed in ICM of bovine embryos as compared to TE [10] suggests that chemokines could be involved in directed movement of Gata6 + cells in the ICM. Here, we show that one of the genes overexpressed in the ICM of bovine embryos, CCL24, does play a role in localization of Gata6 + cells in the bovine embryo. This is so because the percent of Gata6 + cells localized to the outside portion of the ICM was reduced by two antagonists of CCR3, the receptor for CCL24 [26] [27] [28] , as well as by knockdown of mRNA for CCL24. The temporal pattern of expression of CCL24 in the bovine embryo is also consistent with it playing a specific role in blastocyst formation. The gene does not become expressed until Day 6, peaks in the blastocyst at Day 7, and then declines. In vivo, as well, CCL24 transcript was not detected until the blastocyst stage [29] . Moreover, by the blastocyst stage, CCL24 is more expressed in ICM than TE [10, 12, 13, 30] . Present results using an antibody raised to a CCL24 peptide indicated that the protein can be found in both ICM and TE but that intensity of labeling is generally greater for ICM. The variation in the pattern of localization could mean that either the protein can be expressed by cells of the TE or that CCL24 secreted by ICM can move to the TE. One paradox of the present results is that two separate CCR3 antagonists reduced the percent of Gata6 + cells located in the outer region of the ICM even though mRNA for CCR3 and mRNA for a related receptor gene, CCR5, was not detectable in embryos at the blastocyst stage. Similarly, CCR3 was not expressed in bovine embryos produced in vivo from the 2-cell through blastocyst stage [34] and CCR5 transcript was absent in 2-cell, 8-cell, and morula stage embryos, weakly expressed in 4-cell embryos and observed in only one of two pools of 16-cell embryos and one of two pools of blastocysts examined [29] . There are several possible explanations for the paradox. First, it is possible that only a small subset of cells in the ICM express CCR3. Indeed, results from our laboratory (Negrón-Pérez and Hansen, unpublished) using single-cell RT-PCR is indicative that a fraction of cells in the Day 8.75 blastocyst express CCR3. Secondly, it is possible that receptors were synthesized in the oocyte or early embryo and persist through the blastocyst stage despite low transcript abundance. Finally, it is possible that CCL24 uses an alternate receptor other than CCR3 or CCR5 in the ICM. Chemokine receptors share ligands and CCR3 can be activated by at least six chemokines [27, 31, 32] . There are other chemokine receptor genes expressed in the ICM of the bovine blastocyst [10, 12, 30, 29] . It is also possible that the antagonists are blocking receptors distinct from those involved in chemokine signaling, although the fact that the knockdown of CCL24 caused similar effects makes this less likely.
Typically, knockdown of mRNA in embryos is achieved by injection of siRNA into the zygote [33] [34] [35] . However, efficiency of knockdown declines after several days [35] [36] . Given that CCL24 does not become highly expressed until the blastocyst stage, use of siRNA was deemed to be unlikely to reduce transcript abundance for CCL24 in the blastocyst. However, microinjection of morpholinos complementary towards CCL24 was effective at reducing mRNA for CCL24. Morpholinos are oligonucleotides that are complementary to the sequence of the targeting gene and where ribose is substituted with a morpholino ring to increase stability inside the cell [37] . The selected targeting CCL24 morpholino interrupted the splicing region downstream of exon 2 (i.e., intron 2) to produce a nonfunctional CCL24 mRNA.
The fact that large numbers of Gata6 + cells remained in the outer portion of the ICM after treatment with CCR3 inhibitors or the CCL24 morpholino was to be expected even if CCL24 participates in cell positioning. Gata6 + cells are originally dispersed throughout the ICM and then Gata6 + cells become restricted to the hypoblastic epithelium [25] . If a treatment (inhibitor or morpholino) completely prevented the change in position, one would still find Gata6 + cells in the outer part of the ICM, although, as observed here, the percent of cells in the outer portion would be reduced. Although evidence was obtained that CCL24 is involved in hypoblast formation in cattle, the chemokine is not important in blastocyst differentiation in the mouse because the gene is not expressed in the preimplantation embryo and because mating of Ccl24 null females with null males results in live offspring. Expression of Ccl24 in the preimplantation mouse embryo was analyzed in silico by reviewing previous datasets from studies of global gene expression. In none of the studies, which encompassed analysis of oocytes, cleavagestage embryos, and blastocysts up to E4.5, were detectable amounts of Ccl24 consistently identified. This was true whether analysis was performed using microarray analysis or RNA-Seq. Similarly, personal communication from Marc Rothenberg, University of Cincinnati, indicates that female mice homozygous for a deletion in a 4.0 kb fragment of mouse chromosome 5 containing exons 1-3 of Ccl24 [38] bred to homozygous null males for the same deletion produce live young with an average litter size of 4.9 ± 0.5 pups at weaning (3-4 weeks of age). It is likely that the chemokine landscape is different between bovine and mouse embryos not only for CCL24 but also for other chemokines. Besides CCL24 [10, 12, 13, 30, 29] , other chemokine genes expressed in the bovine blastocyst include C-C motif chemokine ligands 17, 25, and 26 (CCL17, CCL25, CCL26), C-X-C motif chemokine ligand 17 (CXCL17), and PPBP [11, 30, 29] . CCL26 is expressed in the polar TE of the bovine embryo [11, 30] and such a location for synthesis of CCL26 could set up a chemokine gradient that facilitates directed movement of Gata6 + cells to the blastocoele. In the mouse, in contrast, Ccl17, Ccl25, Cxcl14, and Ppbp were very low or nondetectable in blastocysts in most [39] [40] [41] [42] [43] but not all [42] transcriptome databases. Moreover, Ccl26 is not expressed in the blastocyst [39] [40] [41] [42] [43] or any other tissue as it is considered a pseudogene [38] . The fact that CCL24 has different roles in the bovine and mouse embryo is not surprising because of species divergence in preimplantation development among mammals including for the mechanisms controlling the first differentiation events in the blastocyst. Following embryonic genome activation, transcription occurs in a species-specific pattern, with that of the bovine and human being more similar to each other than to the mouse [39] . Mutations in the regulatory elements for POU domain, class 5, transcription factor 1 (Pou5f1) (i.e., Oct4) occurring in the mouse mean that expression of this transcription factor is limited to the ICM in the mouse but not in the cow and human [35] . Formation of the hypoblast involves actions of Fgf4 in the mouse [1] [2] [3] [4] but not in the bovine and human [5] . Greater similarity between cattle and humans as compared to the mouse may reflect the high rate of evolutionary change in mice (see discussion in ref. [44] ).
In conclusion, findings of the present experiments indicate that the chemokine CCL24 participates in reorganization of the ICM of the bovine blastocyst to facilitate localization of Gata6 + cells to the outside of the ICM. 
